5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 4.71▲ | 4.70▲ | 4.71▲ | 4.66▼ | 4.50▼ |
MA10 | 4.89▼ | 4.99▼ | 4.97▼ | 4.65▼ | 4.19▲ |
MA20 | 5.09▼ | 5.02▼ | 4.84▼ | 4.63▼ | 2.23▲ |
MA50 | 4.77▼ | 4.77▼ | 5.04▼ | 3.55▲ | 1.29▲ |
MA100 | 4.76▼ | 5.03▼ | 5.30▼ | 1.92▲ | 2.40▲ |
MA200 | 5.04▼ | 3.74▲ | 2.86▲ | 1.25▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.100▼ | -0.078▼ | -0.032▼ | -0.109▼ | 0.292▲ |
RSI | 44.886▼ | 46.344▼ | 47.408▼ | 49.837▼ | 61.315▲ |
STOCH | 5.903▼ | 3.269▼ | 13.227▼ | 28.983 | 60.275 |
WILL %R | -91.290▼ | -91.290▼ | -79.494▼ | -81.356▼ | -45.560 |
CCI | -73.505 | -82.622 | -60.760 | -59.816 | 44.508 |
RSI | $MYNZ RSI(14) Crossed Below 50 | Set Alert |
Tuesday, January 21, 2025 02:30 PM
Mainz Biomed NV (MYNZ), a molecular genetics diagnostic company, on Tuesday announced the launch of the eAArly DETECT 2 feasibility ...
|
Tuesday, January 21, 2025 05:30 AM
Mainz Biomed (MYNZ) announced the launch of eAArly DETECT 2, a U.S. feasibility study to evaluate the Company’s next generation colorectal ...
|
Tuesday, January 21, 2025 05:22 AM
AArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients. Multi-center study expected to comple ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
23/01/25 | 4.52 | 4.63 | 4.22 | 4.41 | 35,745 |
22/01/25 | 4.80 | 4.9283 | 4.39 | 4.50 | 79,869 |
21/01/25 | 5.07 | 5.0901 | 4.5601 | 4.90 | 48,567 |
17/01/25 | 4.87 | 4.87 | 4.45 | 4.83 | 42,867 |
16/01/25 | 5.00 | 5.48 | 4.60 | 4.65 | 95,928 |
15/01/25 | 5.30 | 6.81 | 4.72 | 5.00 | 206,421 |
14/01/25 | 4.68 | 5.38 | 4.6616 | 5.29 | 78,513 |
13/01/25 | 4.55 | 4.77 | 4.24 | 4.67 | 114,895 |
10/01/25 | 3.86 | 4.84 | 3.86 | 4.28 | 173,560 |
08/01/25 | 4.63 | 4.6348 | 3.99 | 3.99 | 50,222 |
|
|
||||
|
|
||||
|
|